Y-111

N/A

Report date: 2026/03/19 17:23:55

Base Information

Drug NameY-111
Drug Alias NameY111Y-111
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 inhibitorsProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1T cell surface glycoprotein CD3
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesWuhan Yzy Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWuhan Yzy Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A